Language
Menu
About Us
Corporate OverviewOur LeadershipOur HistoryOur ValuesScience & InnovationCompliance & Ethics Program
Our Impact
Sustainability
Our Offerings
Generics & Complex GenericsInnovative MedicinesOur ProductsProduct Education
Our People
Our CultureCareer
 Contact Us
Linkdin profile
Close

Press Releases

January 23, 2024

Lupin Receives Tentative Approval from U.S. FDA for Rivaroxaban Tablets USP

January 18, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

January 14, 2024

Lupin Receives Approval from U.S. FDA for Propranolol Hydrochloride Extended-Release Capsules USP

January 10, 2024

Lupin Launches Varenicline Tablets in the United States

January 9, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

January 4, 2024

Lupin Receives Tentative Approval from U.S. FDA for Dapagliflozin and Saxagliptin Tablets

Previous Page12345...91011Next Page
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.com
Elise Titan
Director, U.S. Communications
elisetitan@lupin.com
Smart Guide
CloseClose
Search Product
    Guide
    Consent to Collection Cookie

    This website uses cookies to enhance your overall web browsing experience, provide you with ads tailored to your interests, and allow us to measure our audience and collect other analytical data about the use of our website.

    By clicking "Accept All" you consent to the collection of your personal information (which may include your Consumer Health Data) through 1st and 3rd party cookies (or similar). To edit your cookie preferences, use the options below.

    For more information, please visit our Privacy Statement.

    Accept All CookiesReject All Non-Essential CookiesCookie Preference Center

    Depending on where you live, you may also be able to exercise your right to opt out or withdraw your consent.Do Not Sell/Share My Personal Information.

    Global Privacy Control Detected

    We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.

    Only necessary cookies required for the website to function are enabled.

    Opt-Out Request Honored

    We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.